{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:48:31Z","timestamp":1793728111491,"version":"4.6.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":163,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neuropharm.2022.109294","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:17:44Z","timestamp":1665728264000},"page":"109294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Mescaline: The forgotten psychedelic"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-2980","authenticated-orcid":false,"given":"Ioanna A.","family":"Vamvakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.D.","family":"Narine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.B.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109294_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-8993(80)90997-X","article-title":"Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli","volume":"186","author":"Aghajanian","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109294_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib3","author":"Albaugh"},{"key":"10.1016\/j.neuropharm.2022.109294_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109294_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(02)08701-9","article-title":"Mescaline use for 5700 years [10]","author":"Bruhn","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2022.109294_bib6","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109294_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109294_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/15563650903586745","article-title":"Peyote and mescaline exposures: a 12-year review of a statewide poison center database","volume":"48","author":"Carstairs","year":"2010","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib9","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","article-title":"Dark classics in chemical neuroscience: mescaline","volume":"9","author":"Cassels","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)26849-5","article-title":"Metabolic fate of \u03bd-(3, 4, 5-trimethoxyphenyl)- ethylamine (mescaline) in humans: isolation and identification of 3,4, 5- trimethoxyphenylacetic acid","volume":"145","author":"Charalampous","year":"1964","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109294_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00427703","article-title":"Metabolic fate of mescaline in man","volume":"9","author":"Charalampous","year":"1966","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109294_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0031-9422(97)00240-9","article-title":"Toxic amines and alkaloids from Acacia berlandieri","volume":"46","author":"Clement","year":"1997","journal-title":"Phytochemistry"},{"key":"10.1016\/j.neuropharm.2022.109294_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jps.2600570114","article-title":"In vitro action of mescaline: possible mode of action","volume":"57","author":"Clemente","year":"1968","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)07676-1","article-title":"The absorption, distribution and urinary excretion of mescaline in the dog","volume":"101","author":"Cochin","year":"1951","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109294_bib15","author":"Cohen"},{"key":"10.1016\/j.neuropharm.2022.109294_bib16","series-title":"Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. Molecules","author":"Cumming","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109294_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113894","article-title":"Neurotoxicity of MDMA: main effects and mechanisms","volume":"347","author":"Costa","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.acc.2016.07.004","article-title":"Challenges in laboratory detection of unusual substance abuse: issues with magic mushroom, peyote cactus, khat, and solvent abuse","volume":"78","author":"Dasgupta","year":"2017","journal-title":"Adv. Clin. Chem."},{"issue":"933 93","key":"10.1016\/j.neuropharm.2022.109294_bib19","first-page":"286","article-title":"Mescaline: excitatory effects on acoustic startle are blocked by serotonin2 antagonists","volume":"1987","author":"Davis","year":"1987","journal-title":"Psychopharmacol."},{"issue":"291 29","key":"10.1016\/j.neuropharm.2022.109294_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01567467","article-title":"Studies on mescaline I. Action in schizophrenic patients","volume":"1955","author":"Denber","year":"1955","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.neuropharm.2022.109294_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2016.10.026","article-title":"Classical hallucinogens and neuroimaging: a systematic review of human studies: hallucinogens and neuroimaging","author":"dos Santos","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109294_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi","year":"2005","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib24","series-title":"The Psychopharmacology of Hallucinogenic Agents","first-page":"409","author":"Freedman","year":"1969"},{"key":"10.1016\/j.neuropharm.2022.109294_bib25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0006-2952(70)90378-3","article-title":"Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism","volume":"19","author":"Freedman","year":"1970","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)31486-2","article-title":"The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle","volume":"207","author":"Geyer","year":"1978","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109294_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0028-3908(93)90097-M","article-title":"Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission","volume":"32","author":"Ghansah","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109294_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-2999(88)90203-8","article-title":"Serotonergic regulation of noradrenergic coerulean neurons: electrophysiological evidence for the involvement of 5-HT2 receptors","volume":"154","author":"Gorea","year":"1988","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109294_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31887\/DCNS.2009.11.3\/egmayfrank","article-title":"Neurotoxicity of drugs of abuse - the case of methylenedioxy amphetamines (MDMA, ecstasy), and amphetamines","volume":"11","author":"Gouzoulis-Mayfrank","year":"2022","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1192\/bjp.82.338.203","article-title":"Artificial psychoses produced by mescaline","volume":"82","author":"Guttmann","year":"1936","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0269881119826610","article-title":"Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice","volume":"33","author":"Halberstadt","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib32","series-title":"Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-662-55880-5","article-title":"Effect of hallucinogens on unconditioned behavior","author":"Halberstadt","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109294_bib33","series-title":"International Journal of Neuropsychopharmacology","first-page":"2165","article-title":"Serotonergic hallucinogens as translational models relevant to schizophrenia","author":"Halberstadt","year":"2013"},{"key":"10.1016\/j.neuropharm.2022.109294_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuropharm.2013.01.014","article-title":"Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice","volume":"70","author":"Halberstadt","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109294_bib35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109294_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0041-008X(73)80016-X","article-title":"Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals","volume":"25","author":"Hardman","year":"1973","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00403349","article-title":"Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception","volume":"4","author":"Hartman","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109294_bib38","series-title":"Ueber Pellote. Beitr\u00e4ge zur chemischen undpharmakologischen Kenntniss der Cacteen. II","author":"Heffter","year":"1898"},{"key":"10.1016\/j.neuropharm.2022.109294_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cber.18960290145","article-title":"Ueber cacteenalkalo\u00efde","volume":"29","author":"Heffter","year":"1896","journal-title":"Berichte der Dtsch. Chem. Gesellschaft"},{"key":"10.1016\/j.neuropharm.2022.109294_bib40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","article-title":"Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research","volume":"32","author":"Hermle","year":"1992","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109294_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-979352","article-title":"Blood flow and cerebral laterality in the mescaline model of psychosis","volume":"31","author":"Hermle","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2022.109294_bib42","series-title":"Effects of Mescaline and Lysergic Acid (D-LSD-25)","first-page":"579","author":"Hoch","year":"1952"},{"key":"10.1016\/j.neuropharm.2022.109294_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.609811","article-title":"Cellular uptake of psychostimulants \u2013 are high- and low-affinity organic cation transporters drug traffickers?","volume":"11","author":"Jensen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrn.2015.8","article-title":"Neurobiology of rodent self-grooming and its value for translational neuroscience","volume":"17","author":"Kalueff","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib45","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/jps.2600591202","article-title":"Peyote constituents: chemistry, biogenesis, and biological effects","volume":"59","author":"Kapadia","year":"1970","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib46","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3389\/fphar.2021.794254","article-title":"Receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenethylamines (mescaline derivatives) and related amphetamines","volume":"12","author":"Kolaczynska","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00421558","article-title":"Autoradiographic studies on the distribution of 3H-mescaline in the brain of the marmoset, Callithrix jacchus","volume":"46","author":"Korr","year":"1976","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109294_bib48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pnpbp.2012.01.003","article-title":"Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology","volume":"37","author":"Kyzar","year":"2012","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109294_bib50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109294_bib51","series-title":"Antibiotic Activity of an Extract of Peyote (Lophophora Williamii (Lemaire) Coulter) on JSTOR","author":"McCleary","year":"1960"},{"key":"10.1016\/j.neuropharm.2022.109294_bib52","author":"Merlis"},{"issue":"276 27","key":"10.1016\/j.neuropharm.2022.109294_bib53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"2021","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109294_bib54","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder | Psychiatrist.com [WWW document]","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109294_bib55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0165-1781(89)90081-4","article-title":"Right hemisphere involvement in mescaline-induced psychosis","volume":"29","author":"Oepen","year":"1989","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109294_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jep.2010.07.021","article-title":"New mescaline concentrations from 14 taxa\/cultivars of Echinopsis spp. (Cactaceae) (\u201c San Pedro\u201d) and their relevance to shamanic practice","volume":"131","author":"Ogunbodede","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-007-0926-5","article-title":"Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose","author":"P\u00e1len\u00ed\u010dek","year":"2008","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0006-8993(86)91090-5","article-title":"Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonists","volume":"385","author":"Rasmussen","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109294_bib60","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109294_bib61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jat\/9.4.183","article-title":"A mescaline associated fatality","volume":"9","author":"Reynolds","year":"1985","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib62","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109294_bib63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib64","first-page":"587","article-title":"Neurolepticlike actions of l-methadone: effect on mescaline-induced altered behavior and on tissue levels of mescaline in mice","volume":"14","author":"Shah","year":"1979","journal-title":"Biol. Psychiatr."},{"issue":"422 42","key":"10.1016\/j.neuropharm.2022.109294_bib65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00429548","article-title":"Screening hallucinogenic drugs: systematic study of three behavioral tests","volume":"1975","author":"Silva","year":"1975","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib66","series-title":"Monatshefte f\u00fcr Chemie und verwandte Teile anderer Wissenschaften","first-page":"129","article-title":"\u00dcber dieAnhalonium-Alkaloide","author":"Sp\u00e4th","year":"1919"},{"key":"10.1016\/j.neuropharm.2022.109294_bib67","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s00216-016-9324-3","article-title":"A sensitive method for the determination of hordenine in human serum by ESI+ UPLC-MS\/MS for forensic toxicological applications","volume":"408","author":"Steiner","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.neuropharm.2022.109294_bib68","series-title":"The Antidotal Action of Sodium Succinate in the Mescaline Psychosis","first-page":"328","author":"Stevenson","year":"1957"},{"key":"10.1016\/j.neuropharm.2022.109294_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(83)90544-7","article-title":"Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors","volume":"96","author":"Trulson","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib70","article-title":"The epidemiology of mescaline use: pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects","author":"Uthaug","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib71","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1248\/bpb.18.696","article-title":"3,4,5-Trimethoxyphenylacetaldehyde, an intermediate metabolite of mescaline, is a substrate for microsomal aldehyde oxygenase in the mouse liver","volume":"18","author":"Watanabe","year":"1995","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109294_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00413101","article-title":"Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions","volume":"31","author":"Wolbach","year":"1962","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109294_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109294_bib74","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0014-2999(75)90278-2","article-title":"Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice","volume":"32","author":"Yamamoto","year":"1975","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:22:19Z","timestamp":1758439339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":74,"alternative-id":["S0028390822003537"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109294","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mescaline: The forgotten psychedelic","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109294"}}